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Abstract
Background: Visceral adipose tissue, a biologically active fat depot, has been proposed as a reliable marker for
visceral adiposity and metabolic abnormalities. Effects of such adiposity on LV diastolic function and dyssynchrony
remained largely unknown.
Methods: We assessed pericardial fat (PCF) and thoracic peri-aortic fat (TPAF) by three-dimensional (3D) volume-vender
multi-detector computed tomography (MDCT) (Aquarius 3D Workstation, TeraRecon, San Mateo, CA, USA). Echo-derived
diastolic parameters and tissue Doppler imaging (TDI) defined mitral annular systolic (S’), early diastolic (E’) velocities as
well as LV filling (E/E’) were all obtained. Intra-ventricular systolic (Sys-D) and diastolic (Dias-D) dyssynchrony were
assessed by TDI method.
Results: A total of 318 asymptomatic subjects (mean age: 53.5 years, 36.8 % female) were eligible in this study. Greater
PCF and TPAF were both associated with unfavorable diastolic indices and higher diastolic dyssynchrony (all p < 0.05).
These associations remained relatively unchanged in multi-variate models. PCF and TPAF set at 81.68 & 8.11 ml yielded
the largest sensitivity and specificity (78.6 and 60 % for PCF, 75 and 66.6 % for TPAF, respectively) in predicting
abnormally high LV diastolic dyssynchrony, which was defined as Dias-D≧55 ms.
Conclusion: Increasing visceral adiposity may be associated with adverse effects on myocardium, primarily featured by
worse diastolic function and greater degree of dyssynchrony.
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Background
Heart failure (HF) has emerged as a rapid growing
epidemic in recent years [1]. There has been increasing
academic interest in heart failure with preserved ejection
fraction (HFpEF), which may account for nearly half of
the HF population [2]. Recent studies have shown that
mechanical dyssynchrony, an important pathophysiologic
surrogate associated with myocardial asynergy, is not
solely limited to systolic heart failure, but also exists in
HFpEF and normal QRS duration [3, 4]. Diastolic dysfunc-
tion and its progression are independent predictors of
incident heart failure [5].
Accumulating epidemiologic data have recently sug-
gested that metabolic abnormalities accompanied by obes-
ity, excessive body fat and systemic inflammation can
confer higher heart failure risks [6–9], partially through
left ventricular (LV) remodeling or hypertrophy [10, 11].
Obesity is associated with altered LV remodeling, possibly
due to increased hemodynamic load, neurohormonal acti-
vation, and increased cytokine production [12]. A recent
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study showed that overweight and obesity were independ-
ent predictors of LV diastolic dysfunction [13]. However,
the mechanistic link between excessive visceral adiposity
and LV mechanical asynergy, especially diastolic dysfunc-
tion, remained largely unexplored.
Pericardial fat (PCF), which can be accurately quantified
by various imaging tools and serve as a reliable marker of
visceral adiposity [14, 15], has been recently proposed as
an active source of proatherogenic cytokines that mediate
systemic inflammation and metabolic derangements in
obese subjects [16]. It had also been shown to influence
LV structure and function through mechanical or para-
crine effects, partially due to its anatomic proximity to the
myocardium [17]. We sought to investigate the association
between visceral adiposity and LV diastolic indices in
subjects undergoing cardiovascular health survey.
Methods
Subjects
From 2009 to 2013, we consecutively studied subjects
who attended primary cardiovascular health survey in a
tertiary medical center in Taipei, Taiwan. Participants
with decompensated heart failure, unstable coronary
events, symptomatic angina or those who underwent
hemodialysis were precluded from this primary screen
program. Detailed physical examination was performed
as well as a thorough review of baseline characteristics,
medical history including current smoking behavior and
regular physical activity from structured questionnaires.
Subjects with known cardiovascular disease history de-
fined as previous myocardial infarction, coronary arterial
disease, stroke, prior hospitalization for congestive heart
failure and peripheral arterial disease were excluded.
Subjects with history of atrial fibrillation, left bundle
branch block or pacemaker implantation were also ex-
cluded. A total of 318 subjects after exclusion during
study period were finally enrolled.
Hypertension was defined as systolic blood pressure
higher than 140 mmHg, diastolic blood pressure higher
than 90 mmHg or previously diagnosed hypertension under
medication control. Diabetes was defined as fasting glucose
level more than 126 mg/dL or previously diagnosed
diabetes under medication control. Hyperlipidemia was
defined as those with known history and/or who use lipid-
lowering drugs, such as statins or fibrates, on a daily basis.
This study has been approved by Mackay Memorial
Hospital Institutional Review Board with adherence to re-
search ethics (IRB number: 14MMHIS161). All partici-
pants were adults and provided written informed consent
to be included in the study.
Lab data acquisition and analysis
Hitachi 7170 Automatic Analyzer (Hitachi Corp.
Hitachinaka Ibaraki, Japan) was used to measure fasting
and postprandial glucose levels (hexokinase method),
HbA1c, creatinine (kinetic colorimetric assay), total
cholesterol and triglyceride (TG). Lipid profiles including
low-density lipoprotein (LDL) and high-density lipopro-
tein cholesterol (HDL) were obtained by homogenous en-
zymatic colorimetric assay. High-sensitivity CRP (hs-CRP)
levels were determined by using a highly sensitive, latex
particle-enhanced immunoassay Elecsys 2010 (Roche,
Mannheim, Germany).
Echocardiographic assessment
Each subject underwent two-dimensional and color Dop-
pler transthoracic echocardiogram (GE, Vivid 7, Vingmed
Ultrasound, Norway) equipped with 2–4 MHz transducer
at left decubitus position. Standardized echocardiography
imaging protocol including measurement of left atrial
dimension (LAD), wall thickness, LV volumes (biplane
Simpson method), and LV mass (American Society of
Echocardiography criteria) [18] were all obtained. LV dia-
stolic function was determined by pulsed-wave Doppler of
transmitral inflow early (E) and late diastolic (A) LV filling
velocities measured at the tip of the mitral leaflets in the
apical 4-chamber view. Diastolic functional parameters in-
cluding early mitral inflow velocity (E), early-to-late inflow
ratio (E/A), deceleration time (DT), isovolumetric relax-
ation time (IVRT), and spectral tissue Doppler imaging
(TDI) defined mitral annulus systolic (S’) and early
diastolic (E’) velocities were all obtained. The average
values of S’ and E’ at LV basal lateral and septal segments
were presented throughout this manuscript. Grading of
diastolic dysfunction was then determined according to
EAE/ASE recommendations [19].
For pulsed wave TDI-based measures, highest temporal
resolution with frame rates >100 frames/sec with caution
to optimize the parallel alignment for TDI tracing with
myocardial longitudinal motion was achieved for raw
imaging recording for subsequent dyssynchrony analysis.
Intra-ventricular horizontal dyssynchrony was presented
as the absolute time-to-peak velocity difference of S’ and
E’ (Sys-D, Dias-D) between LV basal lateral and septal
segments from apical 4-chamber views (Additional file 1:
Figure S1). Significant diastolic dyssynchrony was defined
as Dias-D≧55 ms based on a previous article [20].
Measurement of pericardial fat
Multidetector computed tomography (MDCT) study was
performed by a 16-slice scanner (Sensation 16, Siemens
Medical Solutions, Forchheim, Germany) with 16 mm×
0.75 mm collimation, rotation time 420 ms and tube volt-
age of 120 kV. In one breath-hold, images were acquired
from above the level of tracheal bifurcation to below the
base of heart using prospectively ECG triggering with the
centre of the acquisition at 70 % of the R-R interval. From
the raw data, the images were reconstructed with standard
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kernel in 3 mm thick axial, non-overlapping slices and
25 cm field of view. Pericardial fat (PCF) and thoracic
peri-aortic fat (TPAF) were quantified using a dedicated
workstation (Aquarius 3D Workstation, TeraRecon, San
Mateo, CA, USA). The semi-automated segmentation
technique was developed for quantification of fat volumes.
We traced the region of interest manually and defined fat
tissue as pixels within a window of −195 to −45 HU and a
window centre of −120 HU. PCF was defined as any
adipose tissue located within the pericardium from the
level of left main coronary artery to the cardiac base
(Additional file 2: Figure S2A and 2B). TPAF was defined
as all of the adipose tissue surrounding the descending
thoracic aorta which extended 67.5 mm from the
level of the bifurcation of pulmonary arteries with
cranial-caudal coverage. This approach has previously
been validated [21].
Statistical analysis
Continuous data was expressed as the mean and stand-
ard deviation with categorical data expressed as the
frequency and proportion of occurrence in all subjects.
Differences of baseline demographics, metabolic and
echocardiographic parameters between PCF and TPAF
tertile groups were tested by ANOVA test with categor-
ical data analyzed by chi-square or Fisher’s exact test as
appropriate. Uni- and multivariable regression models
including confounding variables of age, gender, BMI,
blood pressure, LV mass index and clinical histories
(hypertension, diabetes, hyperlipidemia, smoking habits)
were used to determine the independent association
between adipose tissue volumes (both PCF & TPAF), LV
structural/functional parameters and degree of dyssyn-
chrony (Sys-D/Dias-D). The area under the receiver-
operator characteristic curve (AUROC) for PCF/TPAF in
identifying significant LV septal and lateral wall (systolic
and diastolic) timing differences was used as a summary
measure of clinical outcome measure for dyssynchrony
(defined as ≧60 & 55 ms for systolic and diastolic dyssyn-
chrony, respectively), with corresponding 95 % confidence
interval (CI) was further reported.
All data were analyzed using a commercial software
STATA 8.2 package (Stata Corp., College Station, Texas).
The significance of p level (α-value) for all analysis was
two-sided, with a value less than 0.05 considered statisti-
cally significant.
Results
Baseline demographics and the association between
visceral adiposity and clinical information
Of all 318 subjects (mean age: 53.5 years, 36.8 % female)
enrolled, 102 (32.1 %) had hypertension, 46 (14.5 %) had
diabetes, and 109 (34.3 %) had hyperlipidemia with a
mean PCF and TPAF volume of 80.6 ± 33 & 7.89 ±
4.47 ml, respectively. Median PCF volume was 75.98 ml
(interquartile range = 39.02), and median TPAF volume
was 7.02 ml (interquartile range = 5.08). The association
between baseline demographics, biochemical data and
visceral adiposity are summarized in the first half of
Table 1. In brief, both higher PCF and TPAF were asso-
ciated with higher systolic blood pressure, male predom-
inance and decreased HDL levels (all p < 0.05). There
were also significant differences in age and diastolic
blood pressure across PCF tertile groups (both p < 0.05).
The association between visceral adiposity, cardiac
geometry and diastolic function
There were 148 subjects with Grade 1 diastolic dysfunc-
tion and 70 subjects with Grade 2 diastolic dysfunction.
The association between echocardiographic data and
visceral adiposity was summarized in the latter half of
Table 1. Across tertile groups, greater PCF and TPAF
were both associated with increased LAD, reduced E
and E’ velocities, lower E/A ratio and prolonged DT
(all p < 0.05). PCF was also associated with elevated
E/E’ ratio, prolonged IVRT and increased interventricular
septum thickness (all p < 0.05). TPAF was associated with
significant increases in LV end-systolic volume and both
wall thickness (all p < 0.05). There was no significant dif-
ference in LV ejection fraction (LVEF) with either adipose
tissue. In Table 2, we re-categorized all subjects into with/
without diastolic dysfunction groups according to EAE/
ASE recommendations [19] and compared their key
characteristics. There were significant differences in age,
gender, both adipose tissue volumes, LA diameter and all
Doppler parameters of diastolic function (all p < 0.05).
Increased BNP was also borderlinely associated with
diastolic dysfunction (p = 0.06).
Figure 1a-d demonstrated the linear regression plots
of PCF/TPAF with E’ and E/E’. Both adipose tissue
volumes had excellent correlation with these two key pa-
rameters of diastolic dysfunction (decreased E’, increased
E/E’; all p < 0.001). In Fig. 2a and b, receiver-operating
characteristic (ROC) analysis showed that both PCF and
TPAF had modest area under curve (AUROC) for identi-
fying diastolic dysfunction (0.712 & 0.666, 95 % CI:
0.651–0.773 & 0.604–0.729 for PCF & TPAF, respect-
ively, both p < 0.001). PCF and TPAF set at 67.31 &
6.69 ml yielded the largest sensitivity and specificity
(72.9 and 62 % for PCF, 62.8 and 60 % for TPAF, respect-
ively) in predicting diastolic dysfunction. It should be
noted here that the p values yielded by ANOVA (Table 1)
and linear regression analysis (Fig. 1d) between TPAF
and E/E’ seemed contradictory. This discrepancy might
be attributed to non-normal distribution of TPAF.
In Table 3, we showed the uni- and multi-variate regres-
sion models regarding the association between visceral
adiposity and various echocardiographic parameters. After
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Table 1 Baseline demographics, biomarkers and echocardiographic parameters categorized by pericardial and periaortic fat volumes
PCF, ml Q1 (n = 106) Q2 (n = 106) Q3 (n = 106) F p-value
<63.6 ml 63.6-88.7 ml >88.7 ml
Age (years) 51.67 ± 8.81 53.60 ± 9.98 55.40 ± 10.29 3.609 0.028
Male 56 (52.8 %) 72 (67.9 %) 73 (68.9 %) - 0.025
BMI (kg/m2) 24.78 ± 3.50 25.48 ± 3.97 25.40 ± 3.41 0.787 0.456
SBP (mmHg) 119.04 ± 17.68 126.30 ± 16.88 127.15 ± 15.20 8.193 <0.001
DBP (mmHg) 74.42 ± 11.17 77.97 ± 9.99 77.62 ± 10.27 5.121 0.006
HbA1c (%) 5.97 ± 0.75 5.97 ± 0.62 6.08 ± 0.73 1.242 0.29
Cholesterol (mg/dL) 201.27 ± 37.52 203.14 ± 37.28 205.33 ± 42.73 0.977 0.378
TG (mg/dL) 137.70 ± 77.21 149.98 ± 90.00 144.72 ± 94.28 0.733 0.481
HDL (mg/dL) 51.50 ± 13.96 50.07 ± 14.13 48.72 ± 13.67 4.12 0.017
LDL (mg/dL) 130.75 ± 33.79 132.18 ± 33.79 135.29 ± 33.23 1.595 0.205
Hs-CRP (mg/dL) 0.174 ± 0.022 0.255 ± 0.035 0.26 ± 0.043 1.312 0.271
BNP (pg/mL) 33.62 ± 6.33 25.64 ± 4.23 32.88 ± 7.19 0.532 0.588
Hypertension 28 (26.4 %) 35 (33 %) 39 (36.8 %) - 0.241
Diabetes 13 (12.3 %) 14 (13.2 %) 19 (17.9 %) - 0.443
Hyperlipidemia 33 (31.1 %) 42 (39.6 %) 34 (32.1 %) - 0.236
LAD (mm) 28.72 ± 5.62 30.51 ± 7.57 32.11 ± 5.15 7.956 <0.001
LVEF (%) 67.81 ± 4.27 67.61 ± 4.92 67.08 ± 5.2 0.657 0.519
LVEDV (ml) 101.03 ± 17.3 103.46 ± 18.97 105.718.91 1.708 0.183
LVESV (ml) 32.36 ± 6.35 33.75 ± 9.14 35.06 ± 9.78 2.622 0.074
LVMI (g/m2) 83.57 ± 14.77 81.03 ± 23.78 84.03 ± 22.36 0.585 0.055
IVS (mm) 9.89 ± 7.95 9.53 ± 1.44 9.88 ± 1.33 0.198 0.028
PWT (mm) 9.84 ± 7.93 9.26 ± 1.37 9.81 ± 1.11 0.522 0.059
E (cm/s) 69.27 ± 15.13 62.3 ± 17.88 61.69 ± 15.39 7.42 0.001
DT (ms) 196.88 ± 32.98 208.7 ± 43 214.72 ± 49.06 4.211 0.016
IVRT (ms) 87.14 ± 13.58 90.91 ± 14.85 92.44 ± 16.49 3.588 0.028
E/A 1.18 ± 0.37 1.04 ± 0.47 0.94 ± 0.24 7.927 <0.001
S’ (cm/s) 7.54 ± 1.71 7.24 ± 1.5 7.11 ± 1.43 2.183 0.114
E’ (cm/s) 8.77 ± 2.06 7.68 ± 2.17 6.75 ± 1.6 28.32 <0.001
E/E’ 7.17 ± 2.21 7.9 ± 4.03 8.49 ± 3.19 5.885 0.003
Diastolic dysfunctiona 52 (49.1 %) 77 (72.6 %) 89 (84 %) - <0.001
Dias-D (ms) 21.42 ± 15.27 26.42 ± 22.18 32.06 ± 25.39 2.258 0.001
Sys-D (ms) 28.21 ± 21.42 31.79 ± 27.6 33.18 ± 29.09 1.838 0.161
TPAF, ml Q1 (n = 106) Q2 (n = 106) Q3 (n = 106) F p-value
<5.71 ml 5.71-8.53 ml >8.53 ml
Age (years) 52.74 ± 9.37 53.53 ± 9.88 54.42 ± 10.17 0.749 0.474
Male 42 (39.6 %) 74 (69.8 %) 85 (80.2 %) - <0.001
BMI (kg/m2) 24.9 ± 3.72 25.42 ± 3.46 25.31 ± 3.74 0.41 0.385
SBP (mmHg) 119.87 ± 17.14 125.48 ± 17.4 127.27 ± 15.51 4.259 0.015
DBP (mmHg) 75.21 ± 11.07 78.9 ± 10.21 75.95 ± 10.13 1.876 0.155
HbA1c (%) 5.96 ± 0.78 5.98 ± 0.64 6.08 ± 0.70 1.141 0.321
Cholesterol (mg/dL) 201.56 ± 36.87 204.7 ± 39.09 203.56 ± 41.8 0.133 0.876
TG (mg/dL) 135.06 ± 77.37 146.32 ± 82.82 151.18 ± 100.5 0.843 0.431
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control of multivariables including age, gender, BMI,
systolic blood pressure, LV mass index and clinical histories
(hypertension, diabetes, hyperlipidemia, smoking habits),
both greater PCF and TPAF remained significantly associ-
ated with increased LAD, lower E/A ratio, reduced E’ vel-
ocity and elevated E/E’ ratio (all p < 0.01).
The association between visceral adiposity and
dyssynchrony
There were 28 subjects with abnormally high diastolic
dyssynchrony (Dias-D≧55 ms) and 22 subjects with
systolic dyssynchrony (Sys-D≧60 ms). As seen in
Table 1, both higher PCF and TPAF were positively
associated with higher degree of diastolic dyssyn-
chrony across tertile groups (both p < 0.01). In Fig. 1e
and f, linear regression plots also showed excellent
correlation between both adipose tissue volumes and
diastolic dyssynchrony (both p < 0.001). In the uni-
and multi-variate regression models of Table 3, we
consistently demonstrated the association between
both visceral adiposities and diastolic dyssynchrony
(adjusted B coefficient: 0.197 & 1.367 for PCF &
TPAF, respectively, both p < 0.001).
Finally in ROC analysis, both PCF and TPAF had opti-
mal AUROC for identifying diastolic dyssynchrony
(0.736 & 0.730, 95 % CI: 0.648–0.824 & 0.621–0.838 for
PCF & TPAF, respectively, both p < 0.001), when defined
by the aforementioned criteria (Dias-D≧55 ms). PCF and
TPAF set at 81.68 & 8.11 ml yielded the largest sensitiv-
ity and specificity (78.6 and 60 % for PCF, 75 and 66.6 %
for TPAF, respectively) in predicting abnormally high LV
diastolic dyssynchrony (Figure 2c and d).
Table 1 Baseline demographics, biomarkers and echocardiographic parameters categorized by pericardial and periaortic fat volumes
(Continued)
HDL (mg/dL) 52.75 ± 14.88 48.85 ± 13.22 48.68 ± 13.33 3.072 0.048
LDL (mg/dL) 129.99 ± 33.17 135.68 ± 34.56 132.64 ± 32.96 0.368 0.68
Hs-CRP (mg/dL) 0.167 ± 0.022 0.216 ± 0.049 0.312 ± 0.047 1.761 0.174
BNP (pg/mL) 26.41 ± 3.93 26.84 ± 5.17 38.89 ± 8.18 1.381 0.253
Hypertension 25 (23.6 %) 39 (36.8 %) 38 (35.8 %) - 0.064
Diabetes 11 (10.4 %) 17 (16 %) 18 (17 %) - 0.321
Hyperlipidemia 36 (33.9 %) 35 (33 %) 38 (35.8 %) - 0.908
LAD (mm) 28.65 ± 6.55 30.3 ± 6.54 32.39 ± 5.32 9.765 <0.001
LVEF (%) 68.23 ± 4.05 67.14 ± 5.09 67.13 ± 5.16 1.851 0.159
LVEDV (ml) 99.98 ± 17.88 105.13 ± 17.79 105.08 ± 19.34 2.755 0.065
LVESV (ml) 31.8 ± 7.5 34.63 ± 8.27 34.74 ± 9.64 4.059 0.018
LVMI (g/m2) 82.11 ± 17.22 85.86 ± 21.18 80.69 ± 22.74 1.663 0.191
IVS (mm) 9.04 ± 1.49 9.48 ± 1.01 10.79 ± 7.88 4.048 0.018
PWT (mm) 8.93 ± 1.11 9.4 ± 1.3 10.58 ± 7.87 3.576 0.029
E (cm/s) 68.78 ± 19.08 65.44 ± 15.23 59.13 ± 13.31 9.465 <0.001
DT (ms) 198 ± 39.47 204.14 ± 38.78 218.22 ± 47.3 4.204 0.016
IVRT (ms) 89.77 ± 14.71 89.82 ± 13.85 90.9 ± 16.84 0.199 0.697
E/A 1.18 ± 0.46 1.06 ± 0.36 0.92 ± 0.28 12.42 <0.001
S’ (cm/s) 7.21 ± 1.52 7.38 ± 1.59 7.31 ± 1.57 0.328 0.072
E’ (cm/s) 8.39 ± 2.34 7.92 ± 1.95 6.89 ± 1.78 15.01 <0.001
E/E’ 7.89 ± 4.05 7.61 ± 2.49 8.06 ± 3.08 0.921 0.399
Diastolic dysfunctiona 59 (55.7 %) 70 (66 %) 89 (84 %) - <0.001
Dias-D (ms) 23.68 ± 18.89 27.21 ± 18.75 32.99 ± 25.63 3.263 0.003
Sys-D (ms) 32.64 ± 25.35 28.49 ± 26.43 32.06 ± 27.01 1.947 0.165
Data are presented as mean ± standard deviation or number (percentage)
aDiastolic dysfunction was determined according to EAE/ASE recommendations [19]
Abbreviations: PCF pericardial fat, TPAF thoracic periaortic fat BMI body-mass-index, SBP systolic blood pressure, DBP diastolic blood pressure, TG triglyceride, LDL
low-density lipoprotein, HDL high-density lipoprotein, Hs-CRP high-senstivity C-reactive protein, BNP brain natriuretic peptide, LVEF left ventricular ejection fraction,
LVEDV left ventricular end-diastolic volume, LVESV left ventricular end-systolic volume, LAD left atrial dimension (M-mode), LVMI left ventricular mass index, IVS
interventricular septum thickness (M-mode), PWT posterior wall thickness (M-mode), E early mitral inflow velocity, A late mitral inflow velocity, DT deceleration
time, IVRT isovolumetric relaxation time, S’ systolic tissue Doppler velocity, E’ early-diastolic tissue Doppler velocity, Dias-D E’ time-to-peak difference (diastolic dys-
synchrony), Sys-D S’ time-to-peak difference (systolic dyssynchrony)
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Discussion
In the present study, we observed that both pericardial
and peri-aortic fat accumulations were significantly
associated with diastolic dysfunction and dyssynchrony
independent of LV mass and traditional risk factors. This
association was slightly tighter with pericardial fat. We
also identified their respective cutoff values for predicting
diastolic dysfunction and dyssynchrony. To our know-
ledge, this is the first study to explore the relationship
between such visceral adiposities and dyssynchrony by
tissue Doppler imaging.
Our team has reported previously that pericardial fat
was independently associated with metabolic derange-
ments, fatty liver disease and systemic inflammation
[14]. Although in this study, the association between
pericardial fat and baseline metabolic risk factors was
mostly weak. This may be explained by the relatively
small sample size and benign clinical status of our par-
ticipants. There was also a lack of correlation with BMI.
Another bivariate analysis between BMI and E/E’ showed
no significant correlation either (r = 0.045, p = 0.423),
which is contrary to most worldwide epidemiologic
studies. One possible explanation of our unusual find-
ings might be that our average BMI is relatively normal
(only 28 subjects had BMI > 30). On the other hand, the
strong correlation that we demonstrated with advanced
tissue Doppler metrics suggested a specific process link-
ing pericardial fat to subclinical diastolic dysfunction
that might be initiated much earlier than systemic meta-
bolic derangements or excessive body mass accumula-
tion. The specific effects of pericardial fat on cardiac
structure and function via various mechanisms have
been proposed in previous literature [22]. Compression
of the heart by this enveloping fat deposit may also
cause impaired LV diastolic filling, leading to atrial re-
modeling and dilation [17]. Pericardial fat also contains
high levels of pro-atherogenic cytokines [23] that may
induce inflammation and collagen turnover, leading to
ventricular stiffness and diastolic dysfunction [24, 25].
Besides LA enlargement, we also observed a slight but
significant increase in LV wall thickness among subjects
with larger PCF or TPAF. Although diastolic dysfunction
or dyssynchrony is not uncommon in people with normal
wall thickness, LV hypertrophy and hypertensive heart
disease are indeed the most important causes of HFpEF
[26, 27]. Therefore, it is reasonable that these changes can
coexist with visceral fat accumulation and diastolic
dysfunction or dyssynchrony. On the other hand, no
significant difference was found with LV mass index, and
multivariate regression analysis also showed that LV mass
Table 2 Baseline demographics, biomarkers and echocardiographic parameters of patients with and without diastolic dysfunctiona
Normal (n = 100) Diastolic dysfunction (n = 218) F p-value
Age (years) 50.82 ± 9.34 54.83 ± 9.8 11.85 0.001
Male 60 (60 %) 141 (64.7 %) - 0.453
PCF (ml) 67.32 ± 31.95 86.79 ± 31.77 25.68 <0.001
TPAF (ml) 6.32 ± 3.73 8.63 ± 4.61 19.24 <0.001
BMI (kg/m2) 25.05 ± 3.78 25.36 ± 4.14 0.415 0.52
HbA1c (%) 4.84 ± 2.44 4.84 ± 2.48 <0.001 0.992
Cholesterol (mg/dL) 195.77 ± 45.85 203.94 ± 42.61 2.399 0.122
LDL (mg/dL) 124.72 ± 42.02 124.98 ± 46.85 0.002 0.963
Hs-CRP (mg/dL) 0.116 ± 0.039 0.166 ± 0.034 1.323 0.251
BNP (pg/mL) 21.03 ± 4.91 35.16 ± 6.7 3.572 0.06
Hypertension 29 (29 %) 73 (33.5 %) - 0.441
Diabetes 12 (12 %) 34 (15.6 %) - 0.493
Hyperlipidemia 40 (40 %) 69 (31.7 %) - 0.162
LAD (mm) 28.76 ± 6.59 31.22 ± 6.08 10.64 0.001
E (cm/s) 68.81 ± 15.22 62.24 ± 16.23 11.7 0.001
DT (ms) 199.95 ± 35.88 210.04 ± 45.27 3.85 0.045
IVRT (ms) 85.66 ± 13.66 92.41 ± 15.49 13.98 <0.001
E’ (cm/s) 10 ± 1.59 6.7 ± 1.42 344.91 <0.001
E/E’ 7.04 ± 1.85 9.63 ± 3.09 60.51 <0.001
Dias-D (ms) 22.62 ± 18.2 30.42 ± 21.66 9.793 0.002
Data are presented as mean ± standard deviation or number (percentage)
aDiastolic dysfunction was determined according to EAE/ASE recommendations [19]
Abbreviations same as Table 1
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Fig. 1 Linear regression scatter plots between E’ and PCF (a), TPAF (b), E/E’ and PCF (c), TPAF (d), Dias-D and PCF (e), TPAF (f). All plots showed
excellent statistical significance (p < 0.001). Abbreviations: PCF = pericardial fat, TPAF = thoracic periaortic fat, E = early mitral inflow velocity,
E’ = early-diastolic tissue Doppler velocity, Dias-D = E’ time-to-peak difference (diastolic dyssynchrony)
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index was a nonfactor, indicating that our primary find-
ings were independent of LV hypertrophy.
Recently, it has been discovered that dyssynchrony is
not as uncommon as previously assumed, and can occur
to some extent even in the normal heart [28]. Due to its
excellent temporal resolution, TDI has been widely utilized
for quantifying the degree of intra-ventricular mechanical
dyssynchrony. Through assessment of systolic myocardial
velocity, TDI has also demonstrated the presence of sub-
clinical systolic dysfunction in HFpEF [29], hypertensive
heart disease and left ventricular hypertrophy [30].
As previously mentioned, both systolic and diastolic
dyssynchrony have been found to exist in HFpEF, though
diastolic dyssynchrony does seem to be more prevalent
and may occur exclusively [3, 4]. This is evident with the
sole presence of diastolic dyssynchrony in our study
Fig. 2 Receiver-operating characteristic curves. a PCF had optimal area under curve (AUROC) for identifying diastolic dysfunction (0.712, p < 0.001).
b TPAF had modest AUROC for identifying diastolic dysfunction (0.666, p < 0.001). c PCF had optimal AUROC for identifying diastolic dyssynchrony
(0.736, p < 0.001) defined as Dias-D≧55 ms. d TPAF had optimal AUROC for identifying diastolic dyssynchrony (0.730, p < 0.001)
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population. Several possible mechanisms have been sug-
gested. First, early diastolic filling is mainly determined
by the coordination of its previous systolic phase.
Discordance of systolic contraction will lead to pro-
longed relaxation and reduced diastolic filling time
[31]. Second, increased afterload may contribute to
diastolic dyssynchrony through elevated wall stress
and myocardial oxygen demand, leading to uneven
distributions in coronary blood flow [32, 33]. Dyssyn-
chrony has been reported to be associated with LV filling
pressure in asymptomatic hypertensive patients with nor-
mal QRS duration and EF [34]. Other etiologies include
conduction system disease, hypertrophy or fibrosis.
One recent study using strain imaging showed that
obesity is a significant independent predictor of intra-
ventricular dyssynchrony [35]. Another TDI-related study
showed significant reductions in myocardial velocities,
global and regional strain among obese subjects [36].
There has been growing interest in the potentially
toxic effects of “cardiac steatosis” (excessive depos-
ition of triglycerides in the myocardial cells) [37],
which may induce myocardial fibrosis, cellular apop-
tosis and mitochondrial dysfunction via free fatty acid
turnover process [38, 39]. Cardiac steatosis may also
be an independent predictor of diastolic dysfunction
in diabetic patients [40].
Due to its proximity to the myocardium and the same
coronary blood supply, pericardial fat may have stronger
correlations with coronary vasculopathy [41], cardiac
structure and function than other measures of adiposity,
such as total visceral fat or subcutaneous fat tissue [42].
The current study results suggest that visceral fat ad-
jacent to cardiac structures may have an independent
role in mediating regional disturbances of coronary
Table 3 Univariate and multivariate regression analyses of pericardial and periaortic fat volumes associated with echocardiographic
parameters
PCF Univariate model Multivariate modela
B Coefficient (unstandardized) 95 % CI p-value B Coefficient (unstandardized) 95 % CI p-value
LVEF −0.008 −0.025-0.009 0.376 −0.003 −0.02-0.013 0.699
LAD 0.043 0.021-0.065 <0.001 0.04 0.018-0.063 <0.001
E −0.015 −0.07-0.04 0.035 −0.021 −0.077-0.036 0.047
DT 0.197 0.049-0.346 0.009 0.148 −0.002-0.298 0.052
IVRT 0.067 0.015-0.12 0.013 0.063 0.008-0.117 0.025
E/A −0.002 −0.003- -0.001 0.003 −0.002 −0.003- -0.001 0.006
E’ −0.024 −0.03- -0.017 <0.001 −0.02 −0.027- -0.013 <0.001
S’ −0.006 −0.012- -0.001 0.021 −0.005 −0.01- 0.001 0.084
E/E’ 0.026 0.016-0.036 <0.001 0.02 0.011-0.03 <0.001
Dias-D 0.211 0.142-0.279 <0.001 0.197 0.128-0.266 <0.001
Sys-D 0.086 0.001-0.174 0.054 0.076 −0.014-0.166 0.096
TPAF
Univariate model Multivariate modela
B Coefficient (unstandardized) 95 % CI p-value B Coefficient (unstandardized) 95 % CI p-value
LVEF −0.045 −0.172-0.082 0.487 −0.007 −0.131-0.117 0.914
LAD 0.377 0.215-0.539 <0.001 0.368 0.204-0.532 <0.001
E −0.283 −0.692-0.127 0.175 −0.335 −0.754-0.085 0.118
DT 2.068 0.973-3.163 <0.001 1.712 0.606-2.819 0.003
IVRT 0.396 0.001-0.791 0.05 0.351 −0.056-0.758 0.091
E/A −0.017 −0.026- -0.009 <0.001 −0.017 −0.026- -0.008 <0.001
E’ −0.164 −0.216- -0.111 <0.001 −0.137 −0.188- -0.086 <0.001
S’ −0.04 −0.081-0.001 0.05 −0.028 −0.069-0.012 0.173
E/E’ 0.176 0.104-0.249 <0.001 0.134 0.064-0.203 <0.001
Dias-D 1.461 0.947-1.976 <0.001 1.367 0.848-1.885 <0.001
Sys-D 0.489 −0.165-1.143 0.142 0.415 −0.258-1.088 0.225
aAdjusted for age, gender, BMI, systolic blood pressure, LV mass index and clinical histories (hypertension, diabetes, hyperlipidemia, smoking habits)
Abbreviations same as Table 1
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supply and cardiac steatosis, resulting in the develop-
ment of intra-ventricular dyssynchrony. Additionally,
the independent association between pericardial fat
burden and increased LA dimension, an important
clinical feature and predictor of HF mechanics beyond
ventricular hypertrophy [43], further highlighted the
possible role of regional adipose depots in mediating
HF development.
Limitations
There are several limitations in our study. The first, our
study has a male gender predominance, which may be
somewhat biased. Secondly, this survey is retrospective
and cross-sectional, without longitudinal follow up or
validation with clinical outcomes. Thirdly, our data come
from asymptomatic Asian participants who underwent
primary cardiovascular health survey, and who therefore
may not be fully representative of the broader general
population in daily out-patient clinics. Finally, only basal
septal and lateral segments were used to calculate
dyssynchrony, which may be an overly simplistic esti-
mate. We also acknowledge that our data regarding LA
remodeling were mainly focused on LA diameter rather
than 2-dimensional echo-based volume measurements.
Conclusion
Our study provides valuable insights into the underlying
of potential pathophysiologic mechanisms that visceral
adipose tissue may exert several biological effects on
myocardial contractile or diastolic functions and coord-
ination, leading to impaired diastolic dysfunction, more
elevated filling pressures and prolonged dyssynchrony,
even in asymptomatic subjects. Our findings are critical
in the conceptual framework of current understanding
in obesity or metabolic derangements related myocardial
asynergy and predisposition to preserved ejection fraction
HF development. Excessive visceral adiposity burden
linked to metabolic derangements, when assessed by CT,
may thus serve as a possible marker or target for associ-
ated diagnostic purposes and future therapeutic interven-
tion in these population.
Additional files
Additional file 1: Figure S1. Pulsed-wave tissue Doppler measurement
of intra-ventricular dyssynchrony. Upper panel: lateral wall TDI waveform.
Lower panel: medial wall TDI waveform. The time intervals between QRS
onset and peak of S’/E’ were measured respectively. Systolic dyssynchrony
was presented as the absolute time-to-peak difference of S’ between lateral
and medial segments (T1-T3). Diastolic dyssynchrony was presented as the
absolute time-to-peak difference of E’ (T2-T4). Abbreviations: Sl = lateral
systolic myocardial velocity, El = lateral early-diastolic myocardial velocity,
Sm=medial systolic myocardial velocity, Em=medial early-diastolic
myocardial velocity. (TIFF 799 kb)
Additional file 2: Figure S2. 3D-reconstruction of total pericardial fat
volume from axial, sagittal and coronal images. Pericardial fat (yellow
color) was selected as all adipose tissue within the pericardial sac and
subtracted from the adjacent cardiac structures. (A) A case with large
pericardial fat (total volume = 174.3 ml). This subject has decreased
diastolic tissue velocity (lateral E’ = 4 cm/s) and prolonged diastolic
dyssynchrony (80 ms). (B) A case with small pericardial fat (total
volume = 26.39 ml). This subject has normal diastolic tissue velocity
(lateral E’ = 12 cm/s) and diastolic dyssynchrony (10 ms). (ZIP 1204 kb)
Abbreviations
HF: Heart failure; HFpEF: Heart failure with preserved ejection fraction;
LV: Left ventricular; PCF: Pericardial fat; E: Early mitral inflow velocity; A: Late
mitral inflow velocity; DT: Deceleration time; IVRT: Isovolumetric relaxation
time; TDI: Tissue Doppler imaging; S’: Systolic tissue Doppler velocity;
E’: Early-diastolic tissue Doppler velocity; Sys-D: S’ time-to-peak difference
(systolic dyssynchrony); Dias-D: E’ time-to-peak difference (diastolic
dyssynchrony); MDCT: Multidetector computed tomography; TPAF: Thoracic
periaortic fat.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
YHL, CJH participated in study design, performed the echocardiographic
measurements and drafted the manuscript. CHY performed the CT
measurements. KTS performed statistical analysis. CHS, TCH, HIY provided
assistance in literature review. TSW, FSY, HGB provided assistance in CT
measurement and method standardization. CLH conceived of this study,
participated in its design and coordination and revised the manuscript.
All authors read and approved the final manuscript.
Acknowledgements
This work was in part supported in part by grants from the National Science
Council (NSC 103-2314-B-010-005-MY3, 103-2314-B-195-001-MY3, 101-2314-B-
195-020–MY1, MOST 103-2314-B-195-006-MY3), and Mackay Memorial
Hospital (10271, 10248, 10220, 10253, 10375, 10358, E-102003).
Author details
1Division of Cardiology, Department of Internal Medicine, Mackay Memorial
Hospital, No. 92, Sec. 2, Zhongshan N. Road, Taipei, Taiwan. 2Division of
Cardiology, Department of Internal Medicine, Mackay Memorial Hospital,
Hsinchu, Taiwan. 3Mackay Junior College of Medicine, Nursing, and
Management, Taipei, Taiwan. 4Mackay Medical College, Taipei, Taiwan.
5Department of Radiology, Mackay Memorial Hospital, Taipei, Taiwan.
6Department of Biomedical Imaging and Radiological Sciences, National
Yang Ming University, Taipei, Taiwan. 7The Institute of Health Policy and
Management, College of Public Health, National Taiwan University, Taipei,
Taiwan. 8University Hospitals Harrington Heart & Vascular Institute, Division of
Cardiology, Case Western Reserve University, Cleveland, OH, USA.
Received: 26 June 2015 Accepted: 26 October 2015
References
1. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, et al.
Heart disease and stroke statistics—2006 update: a report from the
American Heart Association Statistics Committee and Stroke Statistics
Subcommittee. Circulation. 2006;113:e85–e151.
2. Shah SJ, Gheorghiade M. Heart failure with preserved ejection fraction: treat
now by treating comorbidities. JAMA. 2008;300:431–3.
3. Wang J, Kurrelmeyer KM, Torre-Amione G, Nagueh SF. Systolic and diastolic
dyssynchrony in patients with diastolic heart failure and the effect of
medical therapy. J Am Coll Cardiol. 2007;49:88–96.
4. Yu CM, Zhang Q, Yip GWK, Lee PW, Kum LC, Lam YY, et al. Diastolic and
systolic asynchrony in patients with diastolic heart failure: a common but
ignored condition. J Am Coll Cardiol. 2007;49:97–105.
5. Kane GC, Karon BL, Mahoney DW, Redfield MM, Roger VL, Burnett Jr JC,
et al. Progression of left ventricular diastolic dysfunction and risk of heart
failure. JAMA. 2011;306:856–63.
6. Ingelsson E, Sundström J, Arnlöv J, Zethelius B, Lind L. Insulin resistance and
risk of congestive heart failure. JAMA. 2005;294:334–41.
Lai et al. BMC Cardiovascular Disorders  (2015) 15:142 Page 10 of 11
7. Suzuki T, Katz R, Jenny NS, Zakai NA, LeWinter MM, Barzilay JI, et al.
Metabolic syndrome, inflammation, and incident heart failure in the elderly:
the cardiovascular health study. Circ Heart Fail. 2008;1:242–8.
8. Bahrami H, Bluemke DA, Kronmal R, Bertoni AG, Lloyd-Jones DM, Shahar E,
et al. Novel metabolic risk factors for incident heart failure and their
relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis)
study. J Am Coll Cardiol. 2008;51:1775–83.
9. Janssen I, Heymsfield SB, Allison DB, Kotler DP, Ross R. Body mass index and
waist circumference independently contribute to the prediction of
nonabdominal, abdominal subcutaneous, and visceral fat. Am J Clin Nutr.
2002;75:683–8.
10. Turkbey EB, McClelland RL, Kronmal RA, Burke GL, Bild DE, Tracy RP, et al.
The impact of obesity on the left ventricle: the Multi-Ethnic Study of
Atherosclerosis (MESA). JACC Cardiovasc Imaging. 2010;3:266–74.
11. Alpert MA, Lambert CR, Terry BE, Cohen MV, Mukerji V, Massey CV, et al.
Influence of left ventricular mass on left ventricular diastolic filling in
normotensive morbid obesity. Am Heart J. 1995;130:1068–73.
12. Kopelman PG. Obesity as a medical problem. Nature. 2000;404:635–43.
13. Russo C, Jin Z, Homma S, Rundek T, Elkind MS, Sacco RL, et al. Effect of
obesity and overweight on left ventricular diastolic function: a community-
based study in an elderly cohort. J Am Coll Cardiol. 2011;57:1368–74.
14. Lai YH, Yun CH, Yang FS, Liu CC, Wu YJ, Kuo JY, et al. Epicardial adipose
tissue relating to anthropometrics, metabolic derangements and fatty liver
disease independently contributes to serum high-sensitivity C-reactive
protein beyond body fat composition: a study validated with computed
tomography. J Am Soc Echocardiogr. 2012;25:234–41.
15. Doesch C, Suselbeck T, Leweling H, Fluechter S, Haghi D, Schoenberg SO,
et al. Bioimpedance analysis parameters and epicardial adipose tissue
assessed by cardiac magnetic resonance imaging in patients with heart
failure. Obesity (Silver Spring). 2010;18:2326–32.
16. Iacobellis G, Ribaudo MC, Assael F, Vecci E, Tiberti C, Zappaterreno A, et al.
Echocardiographic epicardial adipose tissue is related to anthropometric
and clinical parameters of metabolic syndrome: a new indicator of
cardiovascular risk. J Clin Endocrinol Metab. 2003;88:5163–8.
17. Iacobellis G, Leonetti F, Singh N, Sharma M. Relationship of epicardial
adipose tissue with atrial dimensions and diastolic function in morbidly
obese subjects. Int J Cardiol. 2007;115:272–3.
18. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al.
Recommendations for chamber quantification: a report from the American
Society of Echocardiography’s Guidelines and Standards Committee and the
Chamber Quantification Writing Group, developed in conjunction with the
European Association of Echocardiography, a branch of the European
Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440–63.
19. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, et al.
Recommendations for the evaluation of left ventricular diastolic function by
echocardiography. J Am Soc Echocardiogr. 2009;22:107–33.
20. Shanks M, Bertini M, Delgado V, Ng AC, Nucifora G, van Bommel RJ, et al.
Effect of biventricular pacing on diastolic dyssynchrony. J Am Coll Cardiol.
2010;56:1567–75.
21. Yun CH, Lin TY, Wu YJ, Liu CC, Kuo JY, Yeh HI, et al. Pericardial and thoracic
peri-aortic adipose tissues contribute to systemic inflammation and calcified
coronary atherosclerosis independent of body fat composition,
anthropometric measures and traditional cardiovascular risks. Eur J Radiol.
2012;81:749–56.
22. Sacks HS, Fain JN. Human epicardial adipose tissue: a review. Am Heart J.
2007;153:907–17.
23. Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT, Arafat H, et al.
Human epicardial adipose tissue is a source of inflammatory mediators.
Circulation. 2003;108:2460–6.
24. Martos R, Baugh J, Ledwidge M, O’Loughlin C, Conlon C, Patle A, et al.
Diastolic heart failure: evidence of increased myocardial collagen turnover
linked to diastolic dysfunction. Circulation. 2007;115:888–95.
25. Mak GJ, Ledwidge MT, Watson CJ, Phelan DM, Dawkins IR, Murphy NF, et al.
Natural history of markers of collagen turnover in patients with early
diastolic dysfunction and impact of eplerenone. J Am Coll Cardiol.
2009;54:1674–82.
26. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic
implications of echocardiographically determined left ventricular mass in
the Framingham Heart Study. N Engl J Med. 1990;322:1561–6.
27. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left
ventricular mass and geometry to morbidity and mortality in
uncomplicated essential hypertension. Ann Intern Med. 1991;114:345–52.
28. Zwanenburg JJ, Gotte MJ, Kuijer JP, Heethaar RM, van Rossum AC, Marcus JT.
Timing of cardiac contraction in humans mapped by high-temporal-resolution
MRI tagging: early onset and late peak of shortening in lateral wall. Am J
Physiol Heart Circ Physiol. 2004;286:H1872–80.
29. Yu CM, Lin H, Yang H, Kong SL, Zhang Q, Lee SW. Progression of systolic
abnormalities in patients with “isolated” diastolic heart failure and diastolic
dysfunction. Circulation. 2002;105:1195–201.
30. Wang M, Yip GWK, Wang A, Zhang Y, Ho PY, Tse MK, et al. Tissue Doppler
imaging provides incremental prognostic value in patients with
hypertension and left ventricular hypertrophy. J Hypertension. 2005;23:183–91.
31. Gibson DG, Brown DJ. Relation between diastolic left ventricular wall stress
and strain in man. Br Heart J. 1974;36:1066–77.
32. Bauer M, Cheng S, Unno K, Lin FC, Liao R. Regional cardiac dysfunction and
dyssynchrony in a murine model of afterload stress. PLoS One.
2013;8:e59915.
33. Bonow RO, Vitale DF, Bacharach SL, Frederick TM, Kent KM, Green MV.
Asynchronous left ventricular regional function and impaired global
diastolic filling in patients with coronary artery disease: reversal after
coronary angioplasty. Circulation. 1985;71:297–307.
34. Chang SA, Kim HK, Kim DH, Kim YJ, Sohn DW, Oh BH, et al. Left ventricular
systolic and diastolic dyssynchrony in asymptomatic hypertensive patients.
J Am Soc Echocardiogr. 2009;22:337–42.
35. Purushottam B, Parameswaran AC, Figueredo VM. Dyssynchrony in obese
subjects without a history of cardiac disease using velocity vector imaging.
J Am Soc Echocardiogr. 2011;24:98–106.
36. Tumuklu MM, Etikan I, Kisacik B, Kayikcioglu M. Effect of obesity on left
ventricular structure and myocardial systolic function: assessment by tissue
Doppler imaging and strain/strain rate imaging. Echocardiography.
2007;24:802–9.
37. Chiu HC, Kovacs A, Ford DA, Hsu FF, Garcia R, Herrero P, et al. A novel
mouse model of lipotoxic cardiomyopathy. J Clin Invest. 2001;107:813–22.
38. Gastaldelli A, Morales MA, Marraccini P, Sicari R. The role of cardiac fat in
insulin resistance. Curr Opin Clin Nutr Metab Care. 2012;15:523–8.
39. Christoffersen C, Bollano E, Lindegaard ML, Bartels ED, Goetze JP, Andersen
CB, et al. Cardiac lipid accumulation associated with diastolic dysfunction in
obese mice. Endocrinology. 2003;144:3483–90.
40. Rijzewijk LJ, van der Meer RW, Smit JW, Diamant M, Bax JJ, Hammer S, et al.
Myocardial steatosis is an independent predictor of diastolic dysfunction in
type 2 diabetes mellitus. J Am Coll Cardiol. 2008;52:1793–9.
41. Wang CP, Hsu HL, Hung WC, Yu TH, Chen YH, Chiu CA, et al. Increased
epicardial adipose tissue (EAT) volume in type 2 diabetes mellitus and
association with metabolic syndrome and severity of coronary
atherosclerosis. Clin Endocrinol. 2009;70:876–82.
42. Iacobellis G, Pond CM, Sharma AM. Different “weight” of cardiac and
general adiposity in predicting left ventricle morphology. Obesity
(Silver Spring). 2006;14:1679–84.
43. Melenovsky V, Borlaug BA, Rosen B, Hay I, Ferruci L, Morell CH, et al.
Cardiovascular features of heart failure with preserved ejection fraction
versus nonfailing hypertensive left ventricular hypertrophy in the urban
Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll
Cardiol. 2007;49:198–207.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Lai et al. BMC Cardiovascular Disorders  (2015) 15:142 Page 11 of 11
